Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
04:05pm, Monday, 29'th Sep 2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
uniQure Announces Pricing of Upsized $300 Million Public Offering
11:38pm, Thursday, 25'th Sep 2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
QURE stock skyrockets 200% on ‘three’ big news
02:00pm, Thursday, 25'th Sep 2025
Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday - marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a breakt
QURE stock skyrockets 200% on ‘three' big news
02:00pm, Thursday, 25'th Sep 2025
Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday – marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a brea
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
12:11pm, Thursday, 25'th Sep 2025
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
08:37am, Thursday, 25'th Sep 2025
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease ge
Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?
07:26am, Thursday, 25'th Sep 2025
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
uniQure Stock Jumps On Positive News, But Risks Remain
07:23am, Thursday, 25'th Sep 2025
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in t
UniQure: How QURE Stock Rises 10x To $500?
06:20am, Thursday, 25'th Sep 2025
UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II
Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it
04:37pm, Wednesday, 24'th Sep 2025
A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease.
uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond
04:24pm, Wednesday, 24'th Sep 2025
uniQure N.V. achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 study. Plan for a pre-BLA meeting with the FDA in H2 2025, targeti
uniQure Announces $200 Million Proposed Public Offering
04:06pm, Wednesday, 24'th Sep 2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
uniQure N.V. - Special Call
01:03pm, Wednesday, 24'th Sep 2025
uniQure N.V. - Special Call Company Participants Chiara Russo Matthew Kapusta - CEO & Executive Director Dr. Walid Abi-Saab Kylie O'Keefe - Chief Customer & Strategy Officer Conference Call Participan
A Cure For Huntington's Disease? UniQure Launches More Than 240%.
12:03pm, Wednesday, 24'th Sep 2025
UniQure stock catapulted Wednesday after the company said its experimental gene therapy successfully treated Huntington's disease.
QURE stock skyrockets 200% on ‘three' big news
11:20am, Wednesday, 24'th Sep 2025
Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday – marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a brea
